Multidetector computed tomography angiography predicts the need for bronchial artery embolization in hemoptysis: A retrospective cohort study of 32 patients

多层螺旋CT血管造影预测咯血患者是否需要支气管动脉栓塞术:一项纳入32例患者的回顾性队列研究

阅读:2

Abstract

BACKGROUND: Bronchial artery embolization (BAE) is the standard intervention for severe hemoptysis, yet predicting which patients will require BAE remains challenging. We evaluated whether multidetector computed tomography angiography (MDCTA) findings can predict the need for BAE. METHODS: We retrospectively reviewed 32 consecutive patients hospitalized for hemoptysis >100 mL/day between April 2012 and March 2015. All patients underwent MDCTA on admission and received standardized conservative management. MDCTA findings were dichotomized as (1) normal or mediastinally confined bronchial arteries and (2) abnormally dilated bronchial arteries extending into the pulmonary parenchyma. Interobserver agreement among three readers was assessed (Fleiss κ). The primary outcome was subsequent BAE. RESULTS: Twenty patients had normal/mediastinally confined arteries and 12 had abnormally dilated parenchymal-extending arteries. None of the former required BAE, whereas 7/12 (58 %) in the latter group underwent BAE (p < 0.001). The imaging criterion yielded sensitivity 100 % (95 % CI 59-100 %) and specificity 80 % (95 % CI 59-93 %). Interobserver agreement for the 3-category MDCTA classification was almost perfect (κ = 0.90). Penalized logistic regression adjusting for age, sex, and infectious etiology retained MDCTA parenchymal extension as the sole predictor (adjusted OR ∼18 (p ≈ 0.002)). CONCLUSIONS: MDCTA identification of an abnormally dilated bronchial artery extending into the pulmonary parenchyma predicts BAE requirement in significant hemoptysis. This readily recognizable imaging criterion may expedite interventional consultation and optimize triage.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。